SuperworthCaribou Biosciences price to sales ratio CRBU
Market value divided by revenue over the last twelve months, since 2022.
- Today, Oct 23, 2026
- 5.7×
- 5-year median
- 17.3×
- Against its 5-year history
- 7th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 4.3× to 58.3×
- Peer median
- 1.4×
Caribou Biosciences' price to sales ratio is 5.7× as of Oct 23, 2026.
That is below its 5-year median of 17.3×, lower than on 93% of days in the last 5 years.
Over that time it ranged from 4.3× in Jul 2024 to 58.3× in Mar 2022.
The median for 10 healthcare stocks of a similar size is 1.4×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 5.7× | 4.9× | 20.9× |
| 2025 | 17.1× | 6.8× | 26.9× |
| 2024 | 13.2× | 4.3× | 21.1× |
| 2023 | 14.6× | 9.8× | 43.1× |
| 2022 | 30.1× | 29.5× | 58.3× |
Against its peers
Companies in Healthcare nearest Caribou Biosciences' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| CRBUCaribou Biosciences | 5.7× |
| APTAlpha Pro Tech | 0.9× |
| SPROSpero Therapeutics | 1.4× |
| ATNMActinium Pharmaceuticals | n/m |
| LFVNLifevantage | 0.4× |
| NEPHNephros | 1.9× |
| ICCCImmucell | 3.0× |
| KEQUKewaunee Scientific | 0.3× |
| PDEXPro DEX | 2.6× |
| PLXProtalix BioTherapeutics | 2.5× |
| NATRNatures Sunshine Products | 0.4× |
| Peer median | 1.4× |
Where Caribou Biosciences ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on Caribou Biosciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.